Preeclamptic Patients and Pentraxin 3 & Lipoprotein-associated Phospholipase A2

Completed

• Conditions: Pre-Eclampsia

• Registration Number: NCT04239352
• Lead Sponsor: Kanuni Sultan Suleyman Training and Research Hospital

Brief Summary

In particular, pentraxine 3 (PTX3) molecule was assumed to have a prognostic value in acute myocardial infarction.In patients affected by acute myocardial infarction, early plasma elevation of PTX3 appears to predict a worse outcome in these patients in the longer term.

The inflammatory basis of preeclampsia resembles an atherogenic process.It is planned to investigate the role of these two molecules in endothelial dysfunction typical of preeclampsia.

The level of circulating PTX3 and Lp-PLA2 in preeclamptic patients and their serum levels according to the severity of preeclampsia and presence of IUGR, and comparison with the control group without preeclampsia and It is planned to investigate the cut-off values and sensitivity and specificity of both molecules together and separately in preeclampsia.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-20
• Study First Submitted: 2020-01-20
• Study First Submitted QC: 2020-01-23
• Study First Posted: 2020-01-27
• Status Verified: 2020-05
• Primary Completion: 2020-05-20
• Study Completion: 2020-05-20
• Last Update Submitted: 2020-05-21
• Last Update Posted: 2020-05-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

• pregnant women diagnosed with preeclampsia; The blood pressure and proteinuria (at least ≥ 300 mg in urine for 24 hours) will be established before the 20th week of gestation in normotensive pregnancies with an interval of 6 hours.
• Those who have Grand mal convulsions; other causes of convulsions and exclusion of coma were defined as having seizures for the first time after 20 weeks of gestation and 48-72 hours after delivery.
• The diagnosis of HELLP syndrome will be confirmed by intravascular hemolysis. (Abnormal peripheral smear and / or abnormal bilirubin values), high liver enzymes (high serum aspartate transaminase levels [AST], alanine transferase [ALT] and lactate dehydrogenase [LDH] üst 2 upper level) and low platelet count (<100 000 / mm3)
• healthy pregnant women without additional disease for the control group

Exclusion Criteria

• Maternal diabetes
• Kidney disease
• Cardiovascular disease
• Neurological disease
• drug use history
• Hematological and immunological disease
• The presence of any infection
• Fetal anomaly
• In utero dead fetus

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
study group	1 week	preeclampsia in pregnant women; in the study group; serum Pentraxin 3 \& Lipoprotein-associated phospholipase A levels; It will be investigated whether these parameters observed in pregnant women with preeclampsia vary. Thus, it will be tried to be shown that these new markers may have a place in predicting the risk of preeclampsia
control group	1 week	in healthy pregnant women; in the control group; serum Pentraxin 3 \& Lipoprotein-associated phospholipase A levels; The values of these new parameters in healthy pregnants that constitute the control group will be determined and it will be understood whether there is a difference with the pregnants who developed the preeclampsia

Trial Locations

Locations (1)

Kanuni Sultan Süleyman Training and Research Hospital; 🇹🇷 Istanbul, Turkey